Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
Meet the Executive: Tal Heppenstall, President of UPMC Enterprises
It’s been five years since UPMC rebranded its long-standing work on health care innovation and …
Read More →
Get to know FLIGHT
FLIGHT hopes to create opportunities for professional development and mentorship, cultivate the growth of talented women, and increase engagement of women within the organization.
Read More →
Meet the Executive: Sara Fest, Senior Director of Marketing and Communications
Sara Fest got her first taste of communications work in high school where she picked up photography and was an editor of the school newspaper.
Read More →